A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorRoyal Brompton & Harefield NHS Foundation Trust

About this trial

To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound

A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)

Subject aged > 18 years

Able to willingly give consent

Co-morbidities currently requiring enteral feeding

Weight loss > 10% in preceding 3-6 months

Significant musculoskeletal issues that may impact muscle mass

End of life care (expected < 6 weeks left to live)

30 Participants

are divided into 2 treatment groups

Royal Brompton & Harefield NHS Foundation Trust

Lead sponsor